What Is AOD-9604?
AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH). Published research identifies it as the hGH 177–191 fragment with an additional tyrosine residue at the N-terminus commonly described as Tyr-hGH(177-191). AOD-9604 is therefore a synthetic growth hormone fragment analogue, rather than full-length human growth hormone. It was developed as a defined peptide based on the C-terminal region of hGH, allowing this specific portion of the hormone to be studied separately from the complete protein.
Research Overview Table
Chemical and Molecular Characteristics
AOD-9604 is a synthetic peptide analogue with a molecular structure derived from the carboxyl-terminal region of human growth hormone. Unlike the native hormone, which consists of a 191-amino-acid sequence organized into a complex protein structure, AOD-9604 contains only a modified fragment of the parent molecule. This design results in a considerably smaller and less structurally complex compound than recombinant human growth hormone while also distinguishing it from conventional low-molecular-weight research compounds.
AOD-9604 is a short peptide, so its physicochemical properties are largely shaped by its amino acid composition, peptide bond chemistry, molecular conformation and the placement of charged residues within the sequence. Larger protein biologics often depend on complex folding and post-translational modifications, including glycosylation. Short synthetic peptides usually maintain their molecular identity without these changes.
These structural characteristics are particularly important during laboratory investigations because they influence sample stability, handling procedures, storage requirements and analytical characterization. For this reason, techniques such as high-performance liquid chromatography, liquid chromatography-mass spectrometry, and peptide sequence analysis are commonly used together to verify molecular identity, assess purity, and confirm structural consistency.
Certificates:
Mechanism of Action Under Investigation
A compound-specific molecular mechanism for AOD-9604 has not been fully established. Unlike many peptide-based research compounds that act through a defined receptor or signaling protein, AOD-9604 has not been linked to a verified primary molecular target through direct molecular binding studies. Current mechanistic models are therefore based on experimentally observed biochemical responses rather than on a confirmed receptor-mediated pathway. This distinction is important because the biological activity of the parent hormone cannot automatically be assigned to an isolated peptide fragment.
The strongest mechanistic evidence comes from studies investigating the relationship between AOD-9604 and adipose tissue metabolism. Early experiments examined whether the C-terminal region of human growth hormone contained a discrete domain that could influence lipid metabolism independently of classical growth hormone signaling. Subsequent studies proposed that the β3-adrenergic pathway might contribute to the observed biochemical responses because chronic exposure to AOD-9604 increased β3-adrenergic receptor RNA expression in adipose tissue. However, the same investigations demonstrated that the peptide does not act through direct β3-adrenergic receptor activation. Instead, changes in receptor expression were considered a possible secondary mechanism that could influence lipolytic sensitivity.
Experimental investigations have also shown that AOD-9604 does not behave like intact human growth hormone. Ligand-binding studies found no evidence that the peptide functions as a high-affinity antagonist at the growth hormone receptor, and published studies have not demonstrated direct activation of the classical growth hormone receptor signaling pathway.
Researchers have studied these processes using adipose tissue assays, isolated tissue samples, gene expression analysis, ligand-binding experiments, metabolite measurements, and animal models, including β3-adrenergic receptor knockout mice. These methods helped researchers compare molecular responses with and without specific signaling components. However, several questions remain unanswered. Researchers still need to identify the receptor, validate the molecular target, analyze downstream signaling pathways, and repeat these findings in independent studies to establish a clear mechanism for AOD-9604.
Scientific Research Context
AOD-9604 is known in the scientific literature for its use in experimental models of adipose tissue and lipid metabolism. The research has expanded to include studies of peptide disposition, tissue distribution, metabolic processing, and toxicological assessment. Evidence comes primarily from in vitro systems and preclinical animal models, including cultured adipocytes, isolated adipose tissue preparations, rodent models of obesity, and radiolabeled pharmacokinetic studies.
AOD-9604 Biology and Biological Pathways
Primary Biological Function
The primary biological function examined in direct AOD-9604 studies is adipose tissue metabolism. Experimental models have measured lipolysis, fat oxidation, energy expenditure, and lipolytic sensitivity in adipose tissue. Several studies also evaluated changes in insulin sensitivity to characterize metabolic responses in obese animal models. These biological measurements have been used to quantify adipocyte activity and substrate utilization under experimental conditions.
Relevant Metabolic and Signaling Pathways
Lipid metabolism represents the central pathway in direct AOD-9604 studies. Investigators have measured changes in lipolysis, lipogenesis, fatty acid oxidation, substrate utilization, and energy expenditure to characterize metabolic activity in adipose tissue. β3-adrenergic signaling has also received considerable attention because adipocytes depend on this pathway to regulate lipid mobilization. Experimental findings have shown altered β3-adrenergic receptor expression following chronic treatment, making this pathway an important area of investigation in subsequent studies. However, the pathway has not been completely characterized, and several aspects of its biological role remain unresolved.
Tissue-Specific Biology
Adipose tissue is the dominant biological system in the AOD-9604 literature. White adipose tissue has been used to investigate changes in lipid storage and lipid mobilization because it serves as the primary site of triglyceride accumulation. Brown adipose tissue has also been examined because of its role in substrate oxidation and energy expenditure.
Experimental models have included obese Zucker rats, genetically obese mice, lean control animals, and β3-adrenergic receptor knockout mice. These models allow investigators to compare biological responses across different metabolic states and to examine how adipose tissue function changes under specific experimental conditions. Although a small number of studies have explored cartilage biology, adipose tissue remains the most extensively studied tissue in the direct literature.
Experimental Biomarkers
Lipolysis is the most frequently reported experimental measurement in direct AOD-9604 studies. Investigators have also measured fat oxidation and energy expenditure to evaluate substrate utilization in metabolic models. β3-adrenergic receptor mRNA expression has been quantified in adipose tissue to examine changes in gene expression during chronic exposure experiments. Additional measurements have included body fat and body weight in obese animal models.
Laboratory Investigation Methods
Direct studies have used isolated adipose tissue preparations, obese rodent models, β3-adrenergic receptor knockout mice, and euglycemic clamp techniques to examine metabolic responses associated with AOD-9604. Molecular investigations have included measurements of β3-adrenergic receptor RNA expression in adipose tissue. Nonclinical studies have also incorporated pharmacokinetic analyses in pigs using LC-MS/MS and tissue distribution experiments in rats using ¹⁴C-labeled AOD-9604 and quantitative whole-body radiography. Additional investigations have used genotoxicity assays, including the Ames test, chromosomal aberration assays, and bone micronucleus studies.
Experimental Models Used in Published Research
Direct AOD-9604 studies combine metabolic, pharmacokinetic, distribution, and toxicological models. Most of the published evidence is derived from in vitro systems and preclinical animal studies. Experimental designs include isolated adipose tissue, obese rodent models, β3-adrenergic receptor knockout mice, pharmacokinetic studies in pigs, radiolabeled distribution studies in rats, and long-term toxicology studies in rodents and nonhuman primates.
Isolated Adipose Tissue Preparations
Adipose tissue assays measured lipolytic activity in tissue collected from obese animal models. Additional measurements included adipocyte responses and lipolytic sensitivity in isolated fat tissue. One limitation is that the model is restricted to excised tissue rather than an intact physiological system.
Obese Rodent Models
Studies in obese mice and obese Zucker rats measured body weight, body fat, fat oxidation, energy expenditure, lipolytic sensitivity, and insulin sensitivity. These models were used in both acute and chronic experiments.
β3-Adrenergic Receptor Knockout Mice
β3-adrenergic receptor knockout mice were used to examine the relationship between AOD-9604 and β3-adrenergic signaling. The study compared knockout mice with wild-type controls after both chronic and acute treatment protocols. Experimental measurements included lipolysis, fat oxidation, energy expenditure, body weight, body fat, and β3-adrenergic receptor RNA expression in adipose tissue. The model was limited to experiments involving the β3-adrenergic pathway.
Pharmacokinetic and Tissue Distribution Models
Pharmacokinetic studies in pigs measured plasma AOD-9604 concentrations after intravenous and oral administration. Plasma samples were analyzed by LC/MS/MS to quantify AOD-9604 and its degradation products. Reported measurements included Cmax, Tmax, half-life, and AUC. Rat studies used ¹⁴C-labeled AOD-9604 and quantitative whole-body radiography to measure radioactivity concentrations in tissues following intravenous and oral administration.
Genotoxicity and Chronic Toxicology Models
Genotoxicity studies included a bacterial reverse-mutation assay, a chromosomal aberration assay in CHO cells, and a bone micronucleus assay in rats. Chronic toxicology studies were conducted in Han Wistar rats and cynomolgus monkeys. Assessments included hematology, blood chemistry, urinalysis, ophthalmology, immunogenicity, organ examination, histopathology, and bone analysis.
AOD-9604 Published Research
Adipose Tissue and Metabolic Research
Published studies have investigated AOD-9604 in relation to adipose tissue and metabolic activity. The evidence has been obtained from isolated adipose tissue, obese Zucker rats, obese ob/ob mice, and β3-adrenergic receptor knockout mice. Researchers measured lipolysis, lipolytic sensitivity, fat oxidation, glucose oxidation, plasma glycerol, body weight, body fat, energy expenditure, and insulin sensitivity by using metabolic assays and euglycemic clamp techniques. The available evidence comes primarily from animal models and isolated tissues, and the number of direct studies remains limited.
Pharmacokinetic and Metabolism Research
Published research has also examined the pharmacokinetic behavior and metabolic processing of AOD-9604. The evidence has been derived from pig models together with in vitro serum and urine experiments. Researchers measured plasma concentrations, peptide degradation products, metabolic fragments, Cmax, Tmax, half-life, and area under the curve by using liquid chromatography and tandem mass spectrometry. The published evidence in this area is restricted to a small number of analytical investigations.
Tissue Distribution Research
Studies investigating tissue distribution have used ¹⁴C-labeled AOD-9604 in rat models. Researchers measured radioactivity in different tissues by using quantitative whole-body radiography after oral and intravenous administration. The experiments were performed in animal models only, and the published literature in this area is limited.
Osteoarthritis Research
Published osteoarthritis research used a collagenase-induced rabbit model. The experimental design included four treatment groups that received saline, hyaluronic acid, AOD-9604, or AOD-9604 combined with hyaluronic acid. The reported assessments included gross morphological findings, histopathological findings, and observations of lameness. The evidence in this research area is limited to a single published animal study.
Analytical Detection Research
Published analytical studies have examined the detection and characterization of AOD-9604 and its metabolites. The evidence has been obtained from in vitro experiments designed to identify the parent peptide and its degradation products. Researchers used solid-phase extraction, liquid chromatography, and tandem mass spectrometry to identify multiple metabolites during serum and urine incubation experiments. The available evidence comes from analytical laboratory studies rather than biological models.
Limitations of Current Research
Evidence Is Predominantly Preclinical
The published literature on AOD-9604 consists mainly of experiments in isolated adipose tissue and animal models. Direct studies have used obese ob/ob mice, obese Zucker rats, β3-adrenergic receptor knockout mice, pigs, rabbits, rats, and cynomolgus monkeys. Human studies are described in the literature, but most experimental investigations have been conducted in nonclinical systems.
Human Clinical Evidence
Human studies were conducted during the clinical development of AOD-9604, and phase IIa trials were already underway by February 2002. However, most published reports describe early clinical development, while detailed clinical datasets remain limited. Compared with the experimental literature, relatively few human studies have been described in full publications.
Species Differences
Direct AOD-9604 studies have been performed in multiple species. Metabolic studies used mice and rats, pharmacokinetic studies used pigs, osteoarthritis studies used rabbits, and chronic toxicology studies used cynomolgus monkeys. Because the published evidence was generated in different experimental species, the literature does not provide a single, standardized experimental model across all investigations.
Study Design Limitations
The published studies used markedly different experimental designs. Investigators employed isolated adipose tissue preparations, euglycemic clamp studies, β3-adrenergic receptor knockout models, oral and intravenous pharmacokinetic studies, ¹⁴C-labeled tissue-distribution experiments, bacterial reverse-mutation assays, chromosomal aberration assays, and rabbit osteoarthritis models. The measured endpoints therefore differed substantially between studies.
Independent Replication
The direct literature on AOD-9604 is relatively small. Early metabolic investigations originated from the original development program, while later publications examined analytical detection, in vitro metabolism, and cartilage biology. Only a limited number of studies have examined the same experimental questions using independent experimental designs.
Long-Term Evidence
The longest studies identified in the published literature were 26-week studies in Han Wistar rats and 39-week studies in cynomolgus monkeys. Other direct investigations, including metabolic studies, pharmacokinetic studies, analytical studies, and osteoarthritis experiments, used substantially shorter experimental periods. Long-term evidence outside toxicology studies is limited in the published literature.
Analytical Documentation
Analytical verification is an important part of AOD-9604 research because it helps researchers confirm that the peptide used in laboratory studies matches the expected molecular structure. High-performance liquid chromatography measures purity and identifies impurities. Liquid chromatography-mass spectrometry (LC-MS) is used to confirm molecular identity and measure molecular mass. Nuclear magnetic resonance (NMR), when available, can provide additional information about the peptide's structure.
The analytical documentation most commonly associated with research peptides is a Certificate of Analysis. This document summarizes batch-specific information, including identity, purity, composition and the analytical methods used during testing.
Analytical documentation is intended to confirm the identity and quality of a material in a laboratory setting and it does not demonstrate or predict biological activity or experimental outcomes.
Storage and Laboratory Handling
Store AOD-9604 according to the product specifications. Use standard laboratory procedures during handling, preparation, and storage to prevent contamination. Keep samples properly labeled and store them in appropriate containers. AOD-9604 is intended for laboratory research use only.
Frequently asked questions
Why choose us?
Direct SARMs Croatia is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs Croatia, we aim to make the research supply process simple, clear, and reliable.